Success Metrics

Clinical Success Rate
100.0%

Based on 17 completed trials

Completion Rate
100%(17/17)
Active Trials
0(0%)
Results Posted
94%(16 trials)

Phase Distribution

Ph phase_1
8
47%
Ph phase_2
2
12%
Ph phase_3
7
41%

Phase Distribution

8

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
8(47.1%)
Phase 2Efficacy & side effects
2(11.8%)
Phase 3Large-scale testing
7(41.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

17 of 17 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(17)

Detailed Status

Completed17

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (47.1%)
Phase 22 (11.8%)
Phase 37 (41.2%)

Trials by Status

completed17100%

Recent Activity

0 active trials
Showing 5 of 17
completedphase_1

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

NCT01769404
completedphase_1

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

NCT01784211
completedphase_1

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380
completedphase_1

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

NCT01925989
completedphase_1

A Single Dose Study of LY2605541 in Participants With Liver Impairment

NCT01751399
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT01769404Phase 1

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Completed
NCT01784211Phase 1

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Completed
NCT01654380Phase 1

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Completed
NCT01925989Phase 1

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Completed
NCT01751399Phase 1

A Single Dose Study of LY2605541 in Participants With Liver Impairment

Completed
NCT01877265Phase 1

A Study of LY2605541 in Healthy Participants

Completed
NCT01818245Phase 1

A Study of LY2605541 in Healthy Participants and in the Elderly

Completed
NCT01027871Phase 2

A Study for Patients With Type 2 Diabetes

Completed
NCT01790438Phase 3

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Completed
NCT01792284Phase 3

A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus

Completed
NCT01582451Phase 3

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

Completed
NCT01049412Phase 2

A Study for Patients With Type 1 Diabetes

Completed
NCT01454284Phase 3

A Study in Participants With Type I Diabetes Mellitus

Completed
NCT01468987Phase 3

A Study in Participants With Type 2 Diabetes Mellitus

Completed
NCT01481779Phase 3

A Study in Participants With Type 1 Diabetes Mellitus

Completed
NCT01435616Phase 3

A Study in Patients With Type 2 Diabetes Mellitus

Completed
NCT01871493Phase 1

A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17